By John Carroll With close to $800 million in the bank and an ambitious crew of executives now in charge, Biogen Idec’s research chief says the big biotech is actively hunting out new acquisitions and licensing deals. In an interview with Bloomberg, Doug Williams–the former head of ZymoGenetics until BMS bought the company out–highlighted Biogen’s interest …
By John Carroll After three years of partnering with Switzerland’s Neurimmune Therapeutics on antibody discovery programs targeting the CNS field, Biogen Idec ($BIIB) has opted to seal their deal with a pact to acquire one of its subsidiaries outright for up to $427.5 million. The package kicks off with a $32.5 million upfront and follows with …
By John Carroll Anyone who thought George Scangos (photo) was going to take a business-as-usual approach to running Biogen Idec may want to reassess their thinking. In a Boston Globe interview, Scangos made clear that he intends to expand R&D in areas where the Big Biotech is a leader and jettison anything that doesn’t make the …
